25 January 2024 
EMA/CHMP/22212/2024  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Retsevmo 
selpercatinib 
On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Retsevmo. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. 
The CHMP adopted a new indication to include treatment of adults and adolescents with RET 
fusion-positive thyroid cancer that is radioactive iodine-refractory. For information, the full indications for 
Retsevmo will be as follows:2 
Retsevmo as monotherapy is indicated for the treatment of adults with:  
• 
advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with 
a RET inhibitor 
Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and 
older with: 
•  advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory 
(if radioactive iodine is appropriate) 
• 
advanced RET-mutant medullary thyroid cancer (MTC) 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
